We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

97 hedge funds and large institutions have $252M invested in ARS Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 22

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

28% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 18

13% more call options, than puts

Call options by funds: $4.33M | Put options by funds: $3.83M

11.51% more ownership

Funds ownership: 58.11% → 69.62% (+12%)

5% more funds holding

Funds holding: 92 → 97 (+5)

32% less capital invested

Capital invested by funds: $369M → $252M (-$117M)

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
1.54%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
23
Increased
38
Reduced
22
Closed
18
Calls
$4.33M
Puts
$3.83M
Net Calls
+$502K
Net Calls Change
-$4.2M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$42.3M
2
CST
Charles Schwab Trust
Nevada
+$27.9M
3
Franklin Resources
Franklin Resources
California
+$25.4M
4
KPF
K2 Principal Fund
Ontario, Canada
+$8.4M
5
NCM
Nantahala Capital Management
Connecticut
+$6.03M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$22M
2
RCMNY
Rubric Capital Management (New York)
New York
-$14.2M
3
Two Sigma Investments
Two Sigma Investments
New York
-$3.54M
4
NIP
Nicholas Investment Partners
California
-$1.84M
5
Norges Bank
Norges Bank
Norway
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$41.9M – – –
RCM
2
RA Capital Management
Massachusetts
$35.8M +$42.3M +6,450,000 +214%
O
3
OrbiMed
New York
$34.9M +$3.28M +500,000 +6%
CST
4
Charles Schwab Trust
Nevada
$16.1M +$27.9M +4,246,071 New
SOCM
5
SR One Capital Management
Pennsylvania
$15.2M – – –
Franklin Resources
6
Franklin Resources
California
$14.6M +$25.4M +3,868,509 New
BlackRock
7
BlackRock
New York
$9.7M +$2.01M +305,864 +14%
KPF
8
K2 Principal Fund
Ontario, Canada
$9.65M +$8.4M +1,280,318 +101%
Vanguard Group
9
Vanguard Group
Pennsylvania
$8.02M +$1.81M +276,097 +15%
BBA
10
Baker Bros. Advisors
New York
$7.58M – – –
NI
11
Nextech Invest
Switzerland
$7.22M – – –
Fidelity Investments
12
Fidelity Investments
Massachusetts
$4.94M -$22M -3,357,438 -72%
SCM
13
Sio Capital Management
New York
$4.18M +$3.7M +563,335 +104%
NCM
14
Nantahala Capital Management
Connecticut
$4.15M +$6.03M +918,978 +510%
Millennium Management
15
Millennium Management
New York
$4.15M -$669K -101,931 -8%
SAM
16
Sectoral Asset Management
Quebec, Canada
$3.97M -$1.36M -206,449 -16%
WP
17
Woodline Partners
California
$3.2M +$1.16M +176,967 +26%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.04M +$983K +149,746 +23%
RCMNY
19
Rubric Capital Management (New York)
New York
$2.42M -$14.2M -2,160,000 -77%
State Street
20
State Street
Massachusetts
$2.03M +$641K +97,609 +22%
RA
21
Royce & Associates
New York
$1.75M – – –
TCM
22
Tang Capital Management
California
$1.55M – – –
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$1.41M -$131K -19,912 -5%
Charles Schwab
24
Charles Schwab
California
$1.23M +$1.66M +252,792 +353%
CC
25
Clearline Capital
New York
$1.03M +$1.38M +210,576 +345%
1
2 3 4 5

SPRY Hedge Fund Activity: Q3 2023 in Review

97 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2023, worth a combined $252M — down 32% from $369M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new SPRY positions and 18 closed out — a net gain of 5 holders — while 38 added to existing stakes and 22 trimmed.

The largest buyer was RA Capital Management, adding an estimated $42.3M. The largest seller was Fidelity Investments, cutting an estimated $22M.

  • 97 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2023, up from 92 in Q2 2023.
  • Funds reported $252M of ARS Pharmaceuticals stock for Q3 2023, down 32% quarter-over-quarter.
  • 23 funds opened new ARS Pharmaceuticals positions in Q3 2023 and 18 closed out, a net change of +5 holders.
  • The largest ARS Pharmaceuticals buyer in Q3 2023 was RA Capital Management, an estimated $42.3M added.
  • The largest ARS Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $22M sold.

Based on aggregated 13F filings for Q3 2023.